Zepbound Cost Without Insurance (2026 self-pay)

The Retail Zepbound Price, Dose by Dose

The first thing to know about the Zepbound price is that it does not change as you titrate up. Made by Eli Lilly, Zepbound contains tirzepatide and is prescribed for adults with a BMI of 30+ (obesity) or 27+ (overweight) plus a weight-related condition. Whether you are on the 2.5 mg starter pen or the 15 mg maximum, the list price is the same — so escalating your dose should never raise your bill.

Here is the wholesale acquisition cost (WAC), pen by pen, before any discount touches it:

• 2.5 mg (starting dose, weeks 1-4): $1,060/month
• 5 mg (maintenance): $1,060/month
• 7.5 mg (escalated): $1,060/month
• 10 mg (escalated): $1,060/month
• 12.5 mg (escalated): $1,060/month
• 15 mg (maximum dose): $1,060/month

So at a retail counter with no help, the cash Zepbound price is roughly $1,060/month at every dose. The good news for self-pay patients: Lilly has leaned into cash pricing far harder than Novo Nordisk has with Ozempic and Wegovy. Between LillyDirect pens, cheaper single-dose vials, and the savings card, the price you actually pay can land at a third of that retail number — or lower still if you look at compounded tirzepatide.

What You Pay When Insurance Helps (or Doesn't)

Even if you came here for the Zepbound cost without insurance, it is worth a 30-second check on your plan first — a covered copay can beat every cash route below. Coverage has widened since the November 2023 launch, but what you actually pay still depends heavily on your formulary tier:

Money-saving angle: Mounjaro is the exact same tirzepatide, just approved for diabetes — and some plans cover it when they reject Zepbound. If you have type 2 diabetes, asking your doctor about Mounjaro can turn a $349 cash bill into a low copay. See Mounjaro pricing.

Savings Card and Cash-Pay Programs

Lilly stacks several programs on top of the retail price, and which one wins depends entirely on your insurance status. Here is what each knocks off your monthly bill:

Medicare Pricing From July 2026

If you are on Medicare, your Zepbound price is about to drop sharply. Zepbound is named in the Medicare GLP-1 bridge program that goes live July 1, 2026 — a change that turns a $349 self-pay bill into a modest copay for roughly 7.4 million beneficiaries with obesity.

• Zepbound will be covered for weight management under Medicare Part D
• Estimated copay: $35-$50/month (vs $1,060 list or $349 LillyDirect)
• Prior authorization required: BMI documentation, failed lifestyle modifications
• No age-related dose restrictions — all doses from 2.5mg to 15mg expected to be covered

For anyone currently paying the $349 LillyDirect self-pay price, that is roughly an 85% cut once the bridge program kicks in. Call your Part D plan about the formulary updates expected in Q2 2026 so you switch the moment coverage opens. Read our full Medicare GLP-1 coverage guide.

Cheaper Than Ozempic and Wegovy?

On self-pay price, Zepbound now usually wins. Lilly subsidizes its cash routes far more aggressively than Novo Nordisk does, so the same dollar buys you more tirzepatide than it does semaglutide. Here is how the three stack up out of pocket:

• Ozempic ($998/month list): No manufacturer self-pay program. Best self-pay pricing through telehealth at $199-$349/month. FDA-approved for diabetes only. See Ozempic pricing.
• Wegovy ($1,349/month list): Same semaglutide as Ozempic but for weight loss. Oral Wegovy available at $149/month for the starting dose, but Zepbound shows greater weight loss in clinical trials. See Wegovy pricing.
• Mounjaro ($1,023/month list): Same tirzepatide as Zepbound but for diabetes. If you have type 2 diabetes, Mounjaro may have better insurance coverage. See Mounjaro pricing.

Bottom line on price: if you are buying weight-loss medication with cash, Zepbound at $349/month via LillyDirect is the cheapest brand-name injectable on the board — and compounded tirzepatide drops the number lower still for patients comfortable going that route.